| Description : |
Three high affinity VEGF receptors, Flt-1 (VEGFR-1, activated by placental growth factor PlGF), KDR (Flk-1/VEGFR-2, activated by VEGF), and FLT4 (VEGF3, activated by VEGF-related protein (VRP)), have been identified. These receptors can be divided into three structural regions: seven extracellular Ig-like domains that contain the growth factor binding sites, a single polypeptide chain hydrophobic trans-membrane sequence, and intracellular cytoplasmic domains that confer the tyrosine kinase activity required for signal transduction. Tissue expression of the FLT4 receptor is found predominantly in lymphatic and microvascular endothelium and some leukemia cell lines, indicating that this receptor may be a role in the regulation of hematopoiesis. GenBank NM_182925. The recombinant protein contains the amino acid substitutions V1128L and H1146R with reference to NM_182925. These mutations are reported in GenBank U43143 and GenBank X68203. |
| Source : |
Sf21 |
| Species : |
Human |
| Tag : |
GST |
| Protein length : |
800-end |
| Form : |
0.741mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution. |
| Bio-activity : |
133U/mg, where one unit of Flt4, active activity is defined as 1nmol phosphate incorporated into 500μM (GGEEEEYFELVKKKK) per minute at 30 centigrade with a final ATP concentration of 100μM. |
| Molecular Mass : |
90.9 kDa |
| AA Sequence : |
1 MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID 61 GDVKLTQSMA IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV 121 DFLSKLPEML KMFEDRLCHK TYLNGDHVTH PDFMLYDALD VVLYMDPMCL DAFPKLVCFK 181 KRIEAIPQID KYLKSSKYIA WPLQGWQATF GGGDHPPKSD LEVLFQGPEF KGLRRQSMRR 241 PAHADIKTGY LSIIMDPGEV PLEEQCEYLS YDASQWEFPR ERLHLGRVLG YGAFGKVVEA 301 SAFGIHKGSS CDTVAVKMLK EGATASEQRA LMSELKILIH IGNHLNVVNL LGACTKPQGP 361 LMVIVEFCKY GNLSNFLRAK RDAFSPCAEK SPEQRGRFRA MVELARLDRR RPGSSDRVLF 421 ARFSKTEGGA RRASPDQEAE DLWLSPLTME DLVCYSFQVA RGMEFLASRK CIHRDLAARN 481 ILLSESDVVK ICDFGLARDI YKDPDYVRKG SARLPLKWMA PESIFDKVYT TQSDVWSFGV 541 LLWEIFSLGA SPYPGVQINE EFCQRLRDGT RMRAPELATP AIRRIMLNCW SGDPKARPAF 601 SELVEILGDL LQGRGLQEEE EVCMAPRSSQ SSEEGSFSQV STMALHIAQA DAEDSPPSLQ 661 RHSLAARYYN WVSFPGCLAR GAETRGSSRM KTFEEFPMTP TTYKGSVDNQ TDSGMVLASE 721 EFEQIESRHR QESGFSCKGP GQNVAVTRAH PDSQGRRRRP ERGARGGQVF YNSEYGELSE 781 PSEEDHCSPS ARVTFFTDNS Y |
| Purity : |
Purity 43.7% by SDSPAGE and Coomassie blue staining. |
| Applications : |
Drug Discovery & Development |
| Storage : |
6 months at -70 centigrade. |
| Handling Advice : |
Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into prechilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70 centigrade. |
| Use/Stability : |
On receipt of material store at -70 centigrade. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap. |
